BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol 2018;70:1820-8. [PMID: 29781586 DOI: 10.1002/art.40560] [Cited by in Crossref: 130] [Cited by in F6Publishing: 136] [Article Influence: 32.5] [Reference Citation Analysis]
Number Citing Articles
1 Bayati P, Kalantari M, Assarehzadegan M, Poormoghim H, Mojtabavi N. MiR-27a as a diagnostic biomarker and potential therapeutic target in systemic sclerosis. Sci Rep 2022;12:18932. [DOI: 10.1038/s41598-022-23723-7] [Reference Citation Analysis]
2 Nie M, Kong B, Chen G, Xie Y, Zhao Y, Sun L. MSCs-laden injectable self-healing hydrogel for systemic sclerosis treatment. Bioact Mater 2022;17:369-78. [PMID: 35386467 DOI: 10.1016/j.bioactmat.2022.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Goldman N, Han J, LaChance A. Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases. Clin Cosmet Investig Dermatol 2022;15:2285-312. [PMID: 36320926 DOI: 10.2147/CCID.S360801] [Reference Citation Analysis]
4 Karassa FB, Bougioukas KI, Pelechas E, Skalkou A, Argyriou E, Haidich A. Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses. PLoS ONE 2022;17:e0272327. [DOI: 10.1371/journal.pone.0272327] [Reference Citation Analysis]
5 Robert M, Mouthon L. Esclerodermia o esclerosis sistémica. EMC - Tratado de Medicina 2022. [DOI: 10.1016/s1636-5410(22)46835-8] [Reference Citation Analysis]
6 Maritati F, Provenzano M, Lerario S, Corradetti V, Bini C, Busutti M, Grandinetti V, Cuna V, La Manna G, Comai G. Kidney transplantation in systemic sclerosis: Advances in graft, disease, and patient outcome. Front Immunol 2022;13:878736. [DOI: 10.3389/fimmu.2022.878736] [Reference Citation Analysis]
7 Ramahi A, Hughes M, Khanna D. Practical management of Raynaud's phenomenon - a primer for practicing physicians. Curr Opin Rheumatol 2022;34:235-44. [PMID: 35699336 DOI: 10.1097/BOR.0000000000000877] [Reference Citation Analysis]
8 Wallwork R, Connolly CM, Shneyderman M, Mcmahan Z, Mecoli CA, Wigley F, Hummers LK, Shah AA, Paik JJ. Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis. The Lancet Rheumatology 2022. [DOI: 10.1016/s2665-9913(22)00100-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Giucă A, Gegenava T, Mihai CM, Jurcuţ C, Săftoiu A, Gȋrniţă DM, Popescu BA, Ajmone Marsan N, Jurcuț R. Sclerodermic Cardiomyopathy—A State-of-the-Art Review. Diagnostics 2022;12:669. [DOI: 10.3390/diagnostics12030669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ruaro B, Salton F, Baratella E, Confalonieri P, Geri P, Pozzan R, Torregiani C, Bulla R, Confalonieri M, Matucci-cerinic M, Hughes M. An Overview of Different Techniques for Improving the Treatment of Pulmonary Hypertension Secondary in Systemic Sclerosis Patients. Diagnostics 2022;12:616. [DOI: 10.3390/diagnostics12030616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ananyeva LP, Garzanova LA, Koneva OA, Starovoytova MN, Desinova OV, Ovsyannikova OB, Shayakhmetova RU, Cherkasova MV, Aleksankin AP, Nasonov EL. Anti-topoisomerase 1 antibody level changes after B сell depletion therapy in systemic sclerosis. Naučno-praktičeskaâ revmatologiâ 2022;60:57-63. [DOI: 10.47360/1995-4484-2022-57-63] [Reference Citation Analysis]
12 Xu Z, Chen C. The Downregulation of PTGS2 Mediated by ncRNAs is Tightly Correlated with Systemic Sclerosis-Interstitial Lung Disease. Front Genet 2021;12:795034. [PMID: 35096012 DOI: 10.3389/fgene.2021.795034] [Reference Citation Analysis]
13 Karassa FB, Bougioukas KI, Pelechas E, Skalkou A, Argyriou E, Haidich A. Pharmacological treatment for connective tissue disease-associated interstitial lung involvement: Protocol for an overview of systematic reviews and meta-analyses.. [DOI: 10.1101/2022.01.25.22269807] [Reference Citation Analysis]
14 Lazzaroni MG, Crisafulli F, Moschetti L, Semeraro P, Cunha AR, Neto A, Lojacono A, Ramazzotto F, Zanardini C, Zatti S, Airò P, Tincani A, Franceschini F, Andreoli L. Reproductive Issues and Pregnancy Implications in Systemic Sclerosis. Clin Rev Allergy Immunol 2022. [PMID: 35040084 DOI: 10.1007/s12016-021-08910-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yoshimi R, Nakajima H. The Treatment of Systemic Sclerosis-related Pericarditis. Intern Med . [DOI: 10.2169/internalmedicine.9471-22] [Reference Citation Analysis]
16 de Jesus Guimarães C, da Silva Costa PM, de Brito Vieira Neto J, Guimarães AC. Chemotherapy for Rheumatology. The Golden Guide to Oncologic Pharmacy 2022. [DOI: 10.1007/978-3-030-98596-7_16] [Reference Citation Analysis]
17 Foeldvari I. Sklerodermie bei Kindern und Jugendlichen. Pädiatrische Rheumatologie 2022. [DOI: 10.1007/978-3-662-60410-6_41] [Reference Citation Analysis]
18 Higashioka K, Migita R, Ota T, Uchino A, Niiro H. Successful Treatment of Systemic Sclerosis-related Pericarditis with Mycophenolate Mofetil and Low-dose Prednisolone. Intern Med . [DOI: 10.2169/internalmedicine.8844-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Funatogawa T, Narita Y, Tamura A, Mii K, Sugitani Y, Uchida T. Use of Mycophenolate Mofetil for Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease: Information from a Japanese Hospital Claims Database. Mod Rheumatol 2021:roab111. [PMID: 34850080 DOI: 10.1093/mr/roab111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Saoji AA, Das P, Devi NS. Yoga therapy as an adjunct to conventional management of systemic sclerosis: A case series. J Ayurveda Integr Med 2021;12:705-9. [PMID: 34776323 DOI: 10.1016/j.jaim.2021.06.013] [Reference Citation Analysis]
21 Thoreau B, Chaigne B, Renaud A, Mouthon L. Treatment of systemic sclerosis. Presse Med 2021;50:104088. [PMID: 34718109 DOI: 10.1016/j.lpm.2021.104088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Herrick AL. Raynaud's phenomenon and digital ulcers: advances in evaluation and management. Curr Opin Rheumatol 2021;33:453-62. [PMID: 34420003 DOI: 10.1097/BOR.0000000000000826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zagouras AA, Chatterjee S, Tang WHW. Heart Failure with Preserved Ejection Fraction and Cardiomyopathy: an Under-recognized Complication of Systemic Sclerosis. Curr Treat Options Cardio Med 2021;23. [DOI: 10.1007/s11936-021-00947-w] [Reference Citation Analysis]
24 Torok KS. Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. Rheum Dis Clin North Am 2021;47:757-80. [PMID: 34635303 DOI: 10.1016/j.rdc.2021.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hirata LT, Nunes DDPF, Pereira RDD, Sachetto Z, Pugliesi A. Terapia imunobiológica células B alvo (CD20 e BLyS) em Reumatologia. Rev Paul Reumatol 2021. [DOI: 10.46833/reumatologiasp.2021.20.3.28-33] [Reference Citation Analysis]
26 Syed Gaggatur N, Sange AH, Srinivas N, Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Sange I. Systemic Sclerosis: Highlighting Respiratory Complications and Significance of Early Screening. Cureus 2021;13:e17291. [PMID: 34552830 DOI: 10.7759/cureus.17291] [Reference Citation Analysis]
27 Cottin V, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S, Massol J, Thivolet-Bejui F, Chalabreysse L, Maucort-Boulch D, Jouneau S, Hachulla E, Chollet J, Nasser M. Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France. Front Med (Lausanne) 2021;8:699532. [PMID: 34552943 DOI: 10.3389/fmed.2021.699532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Golovach I, Yehudina Y. Алгоритмы лечения системной склеродермии при преимущественном поражении кожи и суставов, при синдроме Рейно и дигитальных язвах согласно современным рекомендациям. PJS 2018;8:150-8. [DOI: 10.22141/2224-1507.8.4.2018.154132] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Schneider U, Siegert E, Gläser S, Krüger K, Krause A; die Kommission Pharmakotherapie der DGRh. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis]. Z Rheumatol 2021;80:868-78. [PMID: 34545432 DOI: 10.1007/s00393-021-01088-y] [Reference Citation Analysis]
30 Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Journey of a patient with scleroderma from renal failure up to kidney transplantation. World J Transplant 2021; 11(9): 372-387 [PMID: 34631469 DOI: 10.5500/wjt.v11.i9.372] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Gorenflo M, Ziesenitz VC. Treatment of pulmonary arterial hypertension in children. Cardiovasc Diagn Ther 2021;11:1144-59. [PMID: 34527540 DOI: 10.21037/cdt-20-912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Spierings J, Nienhuis H, van Lieshout E, van Laar JM, Pieterse AH. Information preferences about treatment options in diffuse cutaneous systemic sclerosis: A Delphi consensus study. Journal of Scleroderma and Related Disorders 2022;7:42-8. [DOI: 10.1177/23971983211043311] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Naučno-praktičeskaâ revmatologiâ 2021;59:384-393. [DOI: 10.47360/1995-4484-2021-384-393] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Vicente-Rabaneda EF, Serra López-Matencio JM, Ancochea J, Blanco R, González-Gay MÁ, Castañeda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf 2021;:1-23. [PMID: 34433372 DOI: 10.1080/14740338.2021.1973428] [Reference Citation Analysis]
35 Spierings J, Chiu YH, Voortman M, van Laar JM. Autologous stem-cell transplantation in systemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all. Ther Adv Musculoskelet Dis 2021;13:1759720X211035196. [PMID: 34394749 DOI: 10.1177/1759720X211035196] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
36 Kawano-Dourado L, Lee JS. Management of Connective Tissue Disease-Associated Interstitial Lung Disease. Clin Chest Med 2021;42:295-310. [PMID: 34024405 DOI: 10.1016/j.ccm.2021.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Gokcen N. PELVIC FLOOR MUSCLE EXERCISE AND PHYSICAL THERAPY MAY IMPROVE SYSTEMIC SCLEROSIS-ASSOCIATED FECAL INCONTINENCE. CAJMHE 2021;2:104-8. [DOI: 10.47316/cajmhe.2021.2.2.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Midhuna PV, Thappa DM. Simplified guidelines for the management of systemic sclerosis. CSDM 2021;1:24. [DOI: 10.25259/csdm_12_2021] [Reference Citation Analysis]
39 Mattoo H, Pillai S. Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. Cell Mol Life Sci 2021;78:5527-42. [PMID: 34145462 DOI: 10.1007/s00018-021-03874-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
40 Murthy S, Wannick M, Eleftheriadis G, Müller A, Luo J, Busch H, Dalmann A, Riemekasten G, Sadik CD. Immunoglobulin G of systemic sclerosis patients programs a pro-inflammatory and profibrotic phenotype in monocyte-like THP-1 cells. Rheumatology (Oxford) 2021;60:3012-22. [PMID: 33230552 DOI: 10.1093/rheumatology/keaa747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Ma X, Tang R, Luo M, Zeng Z, Shi Y, Tang B, Xiao R. Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Clin Rheumatol 2021;40:3185-93. [PMID: 34080081 DOI: 10.1007/s10067-021-05794-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
42 Yılmaz DD, Borekci S, Musellim B. Comparison of the effectiveness of cyclophosphamide and rituximab treatment in patients with systemic sclerosis-related interstitial lung diseases: a retrospective, observational cohort study. Clin Rheumatol 2021. [PMID: 34056665 DOI: 10.1007/s10067-021-05785-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
43 Hurtubise R, Hudson M, Gyger G, Wang M, Steele RJ, Baron M, Hoa S; Canadian Scleroderma Research Group (CSRG). Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. Respir Med 2021;185:106482. [PMID: 34089970 DOI: 10.1016/j.rmed.2021.106482] [Reference Citation Analysis]
44 Haque A, Hughes M. Raynaud's phenomenon. Clin Med (Lond) 2020;20:580-7. [PMID: 33199324 DOI: 10.7861/clinmed.2020-0754] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
45 Zhu JL, Black SM, Chen HW, Jacobe HT. Emerging treatments for scleroderma/systemic sclerosis. Fac Rev 2021;10:43. [PMID: 34131653 DOI: 10.12703/r/10-43] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Foeldvari I, Torok KS. Review for best practice in clinical rheumatology juvenile systemic sclerosis - Updates and practice points. Best Pract Res Clin Rheumatol 2021;:101688. [PMID: 33896752 DOI: 10.1016/j.berh.2021.101688] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Yoshida Y, Sugimoto T, Hosokawa Y, Suma H, Kobayashi H, Ishitoku M, Kohno H, Tokunaga T, Watanabe H, Mokuda S, Nojima T, Hirata S, Sugiyama E. C-reactive protein and ground-glass opacity as predictors for intractable interstitial lung disease in patients with systemic sclerosis under cyclophosphamide treatment regardless of concomitant glucocorticoids. Mod Rheumatol 2021;:1-8. [PMID: 33775207 DOI: 10.1080/14397595.2021.1907014] [Reference Citation Analysis]
48 Li Q, Wallace L, Patnaik P, Alves M, Gahlemann M, Kohlbrenner V, Raabe C, Wang JR, Garry EM. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study. Rheumatology (Oxford) 2021;60:1915-25. [PMID: 33155024 DOI: 10.1093/rheumatology/keaa547] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
49 Bauhammer J, Fiehn C. Seltene Erkrankungen in der Rheumatologie. Arthritis und Rheuma 2021;41:127-136. [DOI: 10.1055/a-1378-5963] [Reference Citation Analysis]
50 Park R, Nevskaya T, Baron M, Pope JE. Immunosuppression use in early systemic sclerosis may be increasing over time. Journal of Scleroderma and Related Disorders 2022;7:33-41. [DOI: 10.1177/23971983211000971] [Reference Citation Analysis]
51 Innabi A, Gomez-Manjarres D, Alzghoul BN, Chizinga M, Mehrad B, Patel DC. Cyclophosphamide for the treatment of Acute Exacerbation of Interstitial Lung Disease: A Review of the Literature. Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021002. [PMID: 33867789 DOI: 10.36141/svdld.v38i1.11271] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Aringer M, Riemekasten G. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis. Best Pract Res Clin Rheumatol 2021;35:101672. [PMID: 33745826 DOI: 10.1016/j.berh.2021.101672] [Reference Citation Analysis]
53 Ananyeva LP, Tyurin IE, Koneva OA, Garzanova LA, Lila AM. Interstitial lung disease in systemic sclerosis (systemic scleroderma). Sovremennaâ revmatologiâ 2021;15:1-62. [DOI: 10.14412/1996-7012-2021-1s-1-62] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Kang EH, Song YW. Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. Pharmaceuticals (Basel) 2021;14:251. [PMID: 33802193 DOI: 10.3390/ph14030251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Coi A, Barsotti S, Santoro M, Almerigogna F, Bargagli E, Caproni M, Emmi G, Frediani B, Guiducci S, Matucci Cerinic M, Mosca M, Parronchi P, Prediletto R, Selvi E, Simonini G, Tavoni AG, Bianchi F, Pierini A; Rare Diseases Working Group. Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). Orphanet J Rare Dis 2021;16:90. [PMID: 33596949 DOI: 10.1186/s13023-021-01733-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
56 Odler B, Hebesberger C, Hoeflechner L, Pregartner G, Gressenberger P, Jud P, Zenz S, Eller K, Rosenkranz AR, Moazedi-Fuerst F. Effect of short-interval rituximab and high-dose corticosteroids on kidney function in systemic sclerosis: Long-term experience of a single centre. Int J Clin Pract 2021;75:e14069. [PMID: 33540483 DOI: 10.1111/ijcp.14069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Ruaro B, Confalonieri M, Matucci-Cerinic M, Salton F, Confalonieri P, Santagiuliana M, Citton GM, Baratella E, Bruni C. The Treatment of Lung Involvement in Systemic Sclerosis. Pharmaceuticals (Basel) 2021;14:154. [PMID: 33668530 DOI: 10.3390/ph14020154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
58 Hudson M, Ghossein C, Steen V. Scleroderma renal crisis. Presse Med 2021;50:104063. [PMID: 33548376 DOI: 10.1016/j.lpm.2021.104063] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
59 Harlamova EN, Karpenko JJ. Evaluation of the Efficiency of Treatment with Rituximab for Systemic Scleroderma (A Case Report). Arhivʺ vnutrennej mediciny 2021;11:72-75. [DOI: 10.20514/2226-6704-2021-11-1-72-75] [Reference Citation Analysis]
60 Roofeh D, Khanna D. Management of systemic sclerosis: the first five years. Curr Opin Rheumatol 2020;32:228-37. [PMID: 32205570 DOI: 10.1097/BOR.0000000000000711] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
61 Spierings J, van Rhijn-Brouwer FCC, de Bresser CJM, Mosterman PTM, Pieterse AH, Vonk MC, Voskuyl AE, de Vries-Bouwstra JK, Kars MC, van Laar JM. Treatment decision-making in diffuse cutaneous systemic sclerosis: a patient's perspective. Rheumatology (Oxford) 2020;59:2052-61. [PMID: 31808528 DOI: 10.1093/rheumatology/kez579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
62 Zhao M, Wu J, Wu H, Sawalha AH, Lu Q. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. Clin Rev Allergy Immunol 2021. [PMID: 33449302 DOI: 10.1007/s12016-020-08831-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
63 Dou DR, Zhao Y, Abe B, Li R, Zaba LC, Aren K, Carns M, Chung LS, Hinchcliff M, Chang HY. Distinct T cell chromatin landscapes in scleroderma subtypes.. [DOI: 10.1101/2021.01.10.426131] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Koniushevska AA, Parkhomenko TA, Sydorenko NV, Vaizer NV, Balychevtseva IV. SYSTEMIC SCLERODERMIA. LITERATURE REVIEW. VPBM 2021;4:29. [DOI: 10.29254/2077-4214-2021-4-162-29-39] [Reference Citation Analysis]
65 Foeldvari I. Sklerodermie bei Kindern und Jugendlichen. Pädiatrische Rheumatologie 2021. [DOI: 10.1007/978-3-662-60411-3_41-1] [Reference Citation Analysis]
66 Fan YS, Wang B, Wang D, Xu X, Gao C, Li Y, Zhang S, Yang GL, Liu X, Jiang RC, Zhang JN. Atorvastatin combined with low-dose dexamethasone for vascular endothelial cell dysfunction induced by chronic subdural hematoma. Neural Regen Res 2021;16:523-30. [PMID: 32985481 DOI: 10.4103/1673-5374.293152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
67 D’silva KM, Bolster MB. Systemic Sclerosis: A Comprehensive Approach to Diagnosis and Management. Physician Assistant Clinics 2021;6:159-175. [DOI: 10.1016/j.cpha.2020.09.001] [Reference Citation Analysis]
68 Kazem MM, Pope JE. Arthritis in Systemic Sclerosis. In Clinical Practice 2021. [DOI: 10.1007/978-3-030-53736-4_28] [Reference Citation Analysis]
69 Jandali B, Mayes MD. Clinical Management of Tenosynovitis and Tendon Friction Rubs in Systemic Sclerosis. In Clinical Practice 2021. [DOI: 10.1007/978-3-030-53736-4_30] [Reference Citation Analysis]
70 Tang K, Hsu W, Chen C, Tsai M, Yen C, Tseng C. Discovery of triazolyl thalidomide derivatives as anti-fibrosis agents. New J Chem 2021;45:3589-3599. [DOI: 10.1039/d0nj03139a] [Reference Citation Analysis]
71 Bulavko IE, Timofeev EV, Alkak KJU, Isakov VA. Scleroderma nephropathy: unsolved problems. Juvenis scientia 2021;7:5-18. [DOI: 10.32415/jscientia_2021_7_5_5-18] [Reference Citation Analysis]
72 Varrica C, Dias HS, Reis C, Carvalheiro M, Simões S. Targeted delivery in scleroderma fibrosis. Autoimmun Rev 2021;20:102730. [PMID: 33338593 DOI: 10.1016/j.autrev.2020.102730] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
73 Chung L, Spino C, Mclain R, Johnson SR, Denton CP, Molitor JA, Steen VD, Lafyatis R, Simms RW, Kafaja S, Frech TM, Hsu V, Domsic RT, Pope JE, Gordon JK, Mayes MD, Sandorfi N, Hant FN, Bernstein EJ, Chatterjee S, Castelino FV, Ajam A, Allanore Y, Matucci-cerinic M, Whitfield ML, Distler O, Singer O, Young A, Nagaraja V, Fox DA, Furst DE, Khanna D. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. The Lancet Rheumatology 2020;2:e743-53. [DOI: 10.1016/s2665-9913(20)30237-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
74 Barahona-correa JE, De la Hoz A, López MJ, Garzón J, Allanore Y, Quintana-lópez G. Infecciones y esclerosis sistémica: un desafío emergente. Revista Colombiana de Reumatología 2020;27:62-84. [DOI: 10.1016/j.rcreu.2019.12.007] [Reference Citation Analysis]
75 Sist C, Turri M, Florio I, Teatini F. Cranial multineuropathy with hypoglossal nerve involvement in a patient with anti-Ku autoantibodies. Neurol Sci 2021;42:2143-4. [PMID: 33236248 DOI: 10.1007/s10072-020-04912-6] [Reference Citation Analysis]
76 Lentine KL, Lam NN, Caliskan Y, Alhamad T, Xiao H, Schnitzler MA, Chang SH, Axelrod D, Segev DL, McAdams-DeMarco M, Kasiske BL, Hess GP, Brennan DC. Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. Clin Transplant 2020;34:e14118. [PMID: 33048372 DOI: 10.1111/ctr.14118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 McMahan ZH, Khanna D. Managing gastrointestinal complications in patients with systemic sclerosis. Curr Treat Options Gastroenterol 2020;18:531-44. [PMID: 34305387 DOI: 10.1007/s11938-020-00314-x] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Ananieva LP. Current therapy of interstitial pneumonia associated with systemic scleroderma. Naučno-praktičeskaâ revmatologiâ 2020;58:520-531. [DOI: 10.47360/1995-4484-2020-520-531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
79 Renaud A, Durant C, Achille A, Artifoni M, Espitia O, Agard C. [Monocentric study on pharmaceuticals taken by patients to treat systemic sclerosis]. Rev Med Interne 2021;42:86-92. [PMID: 33129579 DOI: 10.1016/j.revmed.2020.08.014] [Reference Citation Analysis]
80 Motta F, Sica A, Selmi C. Frailty in Rheumatic Diseases. Front Immunol 2020;11:576134. [PMID: 33193369 DOI: 10.3389/fimmu.2020.576134] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
81 Vonk MC. Is there still a role for cyclophosphamide in the treatment of systemic sclerosis? Journal of Scleroderma and Related Disorders 2021;6:117-22. [DOI: 10.1177/2397198320961673] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Andréasson K, Neringer K, Wuttge DM, Henrohn D, Marsal J, Hesselstrand R. Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variation-a prospective, observational study. Arthritis Res Ther 2020;22:230. [PMID: 33023643 DOI: 10.1186/s13075-020-02323-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
83 Fallet B, Walker UA. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. Expert Rev Clin Pharmacol 2020;13:1203-18. [PMID: 33008265 DOI: 10.1080/17512433.2020.1832466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Kontzias A, Barkhodari A, Yao Q. Pericarditis in Systemic Rheumatologic Diseases. Curr Cardiol Rep 2020;22:142. [PMID: 32910306 DOI: 10.1007/s11886-020-01415-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
85 Fante MA, Holler B, Weber D, Angstwurm K, Bergler T, Holler E, Edinger M, Herr W, Wertheimer T, Wolff D. Cyclophosphamide for salvage therapy of chronic graft-versus-host disease: a retrospective analysis. Ann Hematol 2020;99:2181-90. [PMID: 32715339 DOI: 10.1007/s00277-020-04193-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
86 McMahan ZH, Volkmann ER. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. Expert Opin Pharmacother 2020;21:2041-56. [PMID: 32674612 DOI: 10.1080/14656566.2020.1793960] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
87 Gosse P, Boulestreau R, Brockers C, Puel C, Rubin S, Cremer A. The pharmacological management of malignant hypertension. Journal of Hypertension 2020;38:2325-30. [DOI: 10.1097/hjh.0000000000002547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
88 Kondoh Y. A new therapy for systemic sclerosis-associated interstitial lung disease. Respiratory Investigation 2020;58:227-229. [DOI: 10.1016/j.resinv.2020.03.005] [Reference Citation Analysis]
89 Hughes M, Khanna D, Pauling JD. Drug initiation and escalation strategies of vasodilator therapies for Raynaud's phenomenon: can we treat to target? Rheumatology (Oxford) 2020;59:464-6. [PMID: 31670800 DOI: 10.1093/rheumatology/kez522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
90 Yamasaki Y, Kuwana M. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology 2020;16:547-60. [DOI: 10.1080/1744666x.2020.1777857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
91 Fernández-codina A, Pope JE. European consensus statements for interstitial lung disease in systemic sclerosis. The Lancet Rheumatology 2020;2:e318-e319. [DOI: 10.1016/s2665-9913(20)30086-2] [Reference Citation Analysis]
92 Volkmann ER, Tashkin DP, LeClair H, Roth MD, Kim G, Goldin J, Clements PJ, Furst DE, Khanna D. Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. ACR Open Rheumatol 2020;2:362-70. [PMID: 32432411 DOI: 10.1002/acr2.11125] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
93 Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM. Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir J 2020;55:1902026. [PMID: 32079645 DOI: 10.1183/13993003.02026-2019] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 33.5] [Reference Citation Analysis]
94 Kuwana M, Ogura T, Makino S, Homma S, Kondoh Y, Saito A, Ugai H, Gahlemann M, Takehara K, Azuma A. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Mod Rheumatol 2021;31:141-50. [PMID: 32243207 DOI: 10.1080/14397595.2020.1751402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
95 Nagaraja V. Management of scleroderma renal crisis. Curr Opin Rheumatol 2019;31:223-30. [PMID: 30870219 DOI: 10.1097/BOR.0000000000000604] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
96 Roofeh D, Jaafar S, Vummidi D, Khanna D. Management of systemic sclerosis-associated interstitial lung disease. Curr Opin Rheumatol 2019;31:241-9. [PMID: 30870216 DOI: 10.1097/BOR.0000000000000592] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
97 Barahona-correa JE, De la Hoz A, López MJ, Garzón J, Allanore Y, Quintana-lópez G. Infections and systemic sclerosis: an emerging challenge. Revista Colombiana de Reumatología (English Edition) 2020;27:62-84. [DOI: 10.1016/j.rcreue.2019.12.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Chung MP, Chung L. Drugs in phase I and phase II clinical trials for systemic sclerosis. Expert Opin Investig Drugs 2020;29:349-62. [PMID: 32178544 DOI: 10.1080/13543784.2020.1743973] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
99 Kelly C. Lung Disease in Rheumatic Disorders. Mediterr J Rheumatol 2019;30:147-54. [PMID: 32185357 DOI: 10.31138/mjr.30.3.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
100 Kuwana M, Distler O. Recent progress and missing gaps to achieve goal in the care of systemic sclerosis–associated interstitial lung disease. Journal of Scleroderma and Related Disorders 2020;5:3-5. [DOI: 10.1177/2397198320902551] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
101 Pope JE. The future of treatment in systemic sclerosis: can we design better trials? The Lancet Rheumatology 2020;2:e185-94. [DOI: 10.1016/s2665-9913(20)30010-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
102 Spierings J, van Laar JM. Choosing a treatment: how can patients be guided through the labyrinth? The Lancet Rheumatology 2020;2:e130-e131. [DOI: 10.1016/s2665-9913(20)30026-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Volkmann ER, Varga J. Emerging targets of disease-modifying therapy for systemic sclerosis. Nat Rev Rheumatol 2019;15:208-24. [PMID: 30796362 DOI: 10.1038/s41584-019-0184-z] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 33.0] [Reference Citation Analysis]
104 Fernández-Codina A, Kazem M, Pope JE. Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. Clin Rheumatol 2020;39:963-5. [PMID: 32016657 DOI: 10.1007/s10067-020-04966-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Pope JE. Recommendations for the Treatment of Systemic Sclerosis: Agreement May Not Translate into Uptake. J Rheumatol 2020;47:164-165. [DOI: 10.3899/jrheum.190582] [Reference Citation Analysis]
106 Hoffmann-vold A, Maher TM, Philpot EE, Ashrafzadeh A, Barake R, Barsotti S, Bruni C, Carducci P, Carreira PE, Castellví I, Del Galdo F, Distler JHW, Foeldvari I, Fraticelli P, George PM, Griffiths B, Guillén-del-castillo A, Hamid AM, Horváth R, Hughes M, Kreuter M, Moazedi-fuerst F, Olas J, Paul S, Rotondo C, Rubio-rivas M, Seferian A, Tomčík M, Uzunhan Y, Walker UA, Więsik-szewczyk E, Distler O. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. The Lancet Rheumatology 2020;2:e71-83. [DOI: 10.1016/s2665-9913(19)30144-4] [Cited by in Crossref: 115] [Cited by in F6Publishing: 119] [Article Influence: 57.5] [Reference Citation Analysis]
107 Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res 2020;21:32. [PMID: 31996266 DOI: 10.1186/s12931-020-1296-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
108 Misra DP, Ahmed S, Agarwal V. Is biological therapy in systemic sclerosis the answer? Rheumatol Int 2020;40:679-94. [PMID: 31960079 DOI: 10.1007/s00296-020-04515-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
109 Sakkas LI. Systemic Sclerosis (Scleroderma). Absolute Rheumatology Review 2020. [DOI: 10.1007/978-3-030-23022-7_11] [Reference Citation Analysis]
110 Tyndall A. Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Review of Current Status. BioDrugs 2019;33:401-9. [PMID: 31302863 DOI: 10.1007/s40259-019-00364-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
111 Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. Naučno-praktičeskaâ revmatologiâ 2019;57:1-40. [DOI: 10.14412/1995-4484-2019-3-40] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
112 Kuwana M, Azuma A. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. Mod Rheumatol 2020;30:225-31. [PMID: 31747840 DOI: 10.1080/14397595.2019.1696505] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
113 Fischer A, Patel NM, Volkmann ER. Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention. Open Access Rheumatol 2019;11:283-307. [PMID: 31849543 DOI: 10.2147/OARRR.S226695] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
114 Yang L, Wang Q, Hou Y, Zhao J, Li M, Xu D, Zeng X. The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center. Clin Rheumatol 2020;39:813-21. [PMID: 31713733 DOI: 10.1007/s10067-019-04784-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
115 Sandler RD, Matucci-Cerinic M, Hughes M. Musculoskeletal hand involvement in systemic sclerosis. Semin Arthritis Rheum 2020;50:329-34. [PMID: 31812353 DOI: 10.1016/j.semarthrit.2019.11.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
116 Chew CY, Mar A, Nikpour M, Saracino AM. Hydroxychloroquine in dermatology: New perspectives on an old drug. Australas J Dermatol 2020;61:e150-7. [PMID: 31612996 DOI: 10.1111/ajd.13168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
117 Distler O, Volkmann ER, Hoffmann-Vold AM, Maher TM. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol 2019;15:1009-17. [PMID: 31566449 DOI: 10.1080/1744666X.2020.1668269] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
118 Becker MO, Distler O, Maurer B. Systemische Sklerose – klinisches Bild, Diagnostik und Therapie. Hautarzt 2019;70:723-741. [DOI: 10.1007/s00105-019-4454-0] [Reference Citation Analysis]
119 Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol 2019;38:2673-81. [PMID: 31423560 DOI: 10.1007/s10067-019-04720-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 8.3] [Reference Citation Analysis]
120 Pauling JD, Hughes M, Pope JE. Raynaud's phenomenon-an update on diagnosis, classification and management. Clin Rheumatol 2019;38:3317-30. [PMID: 31420815 DOI: 10.1007/s10067-019-04745-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 13.3] [Reference Citation Analysis]
121 Wijsenbeek M, Kreuter M, Olson A, Fischer A, Bendstrup E, Wells CD, Denton CP, Mounir B, Zouad-Lejour L, Quaresma M, Cottin V. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 2019;35:2015-24. [PMID: 31328965 DOI: 10.1080/03007995.2019.1647040] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 30.0] [Reference Citation Analysis]
122 Ananyeva LP, Koneva OA, Desinova OV, Garzanova LA, Glukhova SI, Starovoitova MN, Ovsyannikova OB, Volkov AV, Aleksankin AP, Nasonov EL. Effect of rituximab on the manifestations of activity and pulmonary function in patients with systemic sclerosis: one-year follow-up evaluation. Naučno-praktičeskaâ revmatologiâ 2019;57:265-273. [DOI: 10.14412/1995-4484-2019-265-273] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
123 Maher TM, Wuyts W. Management of Fibrosing Interstitial Lung Diseases. Adv Ther 2019;36:1518-31. [PMID: 31119691 DOI: 10.1007/s12325-019-00992-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
124 Becker MO, Distler O, Maurer B. Systemische Sklerose – klinisches Bild, Diagnostik und Therapie. Z Rheumatol 2019;78:439-457. [DOI: 10.1007/s00393-019-0639-2] [Reference Citation Analysis]
125 Johnson SR, Devakandan K. Guidelines and Recommendations Towards Evidence-Based Management of Systemic Sclerosis. Curr Treat Options in Rheum 2019;5:115-126. [DOI: 10.1007/s40674-019-00120-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Wollin L, Distler JH, Denton CP, Gahlemann M. Rationale for the evaluation of nintedanib as a treatment for systemic sclerosis–associated interstitial lung disease. Journal of Scleroderma and Related Disorders 2019;4:212-8. [DOI: 10.1177/2397198319841842] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
127 Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 2019;78:979-87. [PMID: 30967395 DOI: 10.1136/annrheumdis-2018-214816] [Cited by in Crossref: 99] [Cited by in F6Publishing: 106] [Article Influence: 33.0] [Reference Citation Analysis]
128 Bruni C, Shirai Y, Kuwana M, Matucci-cerinic M. Cyclophosphamide: similarities and differences in the treatment of SSc and SLE. Lupus 2019;28:571-4. [DOI: 10.1177/0961203319840433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
129 Pauling JD, Nagaraja V, Khanna D. Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. Curr Treat Options in Rheum 2019;5:85-103. [DOI: 10.1007/s40674-019-00118-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
130 Fernández-codina A, Cañas-ruano E, Pope JE. Management of Raynaud’s phenomenon in systemic sclerosis—a practical approach. Journal of Scleroderma and Related Disorders 2019;4:102-10. [DOI: 10.1177/2397198318823951] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]